Mehdi Khellaf
Overview
Explore the profile of Mehdi Khellaf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Habibi A, Mekontso-Dessap A, Guillaud C, Michel M, Razazi K, Khellaf M, et al.
Am J Hematol
. 2016 Jun;
91(10):989-94.
PMID: 27348613
Delayed hemolytic transfusion reaction (DHTR) is one of the most feared complications of sickle-cell disease (SCD). We retrospectively analyzed the clinical and biological features, treatments and outcomes of 99 DHTRs...
32.
Grimaldi-Bensouda L, Nordon C, Michel M, Viallard J, Adoue D, Magy-Bertrand N, et al.
Haematologica
. 2016 May;
101(9):1039-45.
PMID: 27229715
This prospective observational cohort study aimed to explore the clinical features of incident immune thrombocytopenia in adults and predictors of outcome, while determining if a family history of autoimmune disorder...
33.
Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, et al.
Ann Hematol
. 2015 Sep;
94(12):1973-80.
PMID: 26341755
Thrombopoietin receptor agonists increase platelet counts and reduce bleeding risk in patients with immune thrombocytopenia (ITP). Studies have reported that these agents may represent a risk factor for thromboembolic events,...
34.
Sauvetre G, Mahevas M, Limal N, Guillaud C, Khellaf M, Bierling P, et al.
Am J Hematol
. 2015 Jun;
90(10):E201-2.
PMID: 26120067
No abstract available.
35.
Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard J, Cheze S, et al.
Blood
. 2014 Oct;
124(22):3228-36.
PMID: 25293768
We conducted a prospective multicenter registry of 248 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response and predictive factors of sustained response....
36.
Loustau V, Debouverie O, Canoui-Poitrine F, Baili L, Khellaf M, Touboul C, et al.
Br J Haematol
. 2014 Jun;
166(6):929-35.
PMID: 24957165
In women with pre-existing immune thrombocytopenic purpura (ITP), the effect of pregnancy on the course of the disease is poorly known. We performed a dual-centre retrospective cohort study of 118...
37.
Roumier M, Loustau V, Guillaud C, Languille L, Mahevas M, Khellaf M, et al.
Am J Hematol
. 2014 May;
89(9):E150-5.
PMID: 24847759
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease with poorly known natural history and management remaining mainly empirical. To better describe the characteristics and outcome of wAIHA in...
38.
Audard V, Moutereau S, Vandemelebrouck G, Habibi A, Khellaf M, Grimbert P, et al.
Orphanet J Rare Dis
. 2014 May;
9:67.
PMID: 24779676
Background: The pathophysiologic mechanisms classically involved in sickle-cell nephropathy include endothelial dysfunction and vascular occlusion. Arguments demonstrating that ischemia-reperfusion injury-related kidney damage might coincide with vaso-occlusive crisis (VOC) are lacking....
39.
Mahevas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, et al.
Br J Haematol
. 2014 Apr;
165(6):865-9.
PMID: 24725224
Thrombopoietin-receptor agonists (Tpo-RAs) are highly effective in immune thrombocytopenia (ITP). Recently, cases of durable remission after Tpo-RA discontinuation in adult ITP have been reported. We aimed to describe the subset...
40.
Charles P, Neel A, Tieulie N, Hot A, Pugnet G, Decaux O, et al.
Rheumatology (Oxford)
. 2013 Nov;
53(3):532-9.
PMID: 24282319
Objectives: Rituximab has been shown to induce remission of ANCA-associated vasculitides (AAVs). Our study was undertaken to describe AAV clinical responses to rituximab used for remission-induction and/or maintenance therapy, assess...